Who are DTaP-IPV and ActHIB®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, TT infant whole Pertussis, COVAX only (1st and 2nd dose), vaccinated with bOPV, VI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dtap-ipv-and-acthib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

DTaP-IPV and ActHIB® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DTaP-IPV and ActHIB® (DTaP-IPV and ActHIB®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

phase 3 Vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

DTaP-IPV and ActHIB® (DTaP-IPV and ActHIB®) — Sanofi Pasteur, a Sanofi Company. This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DTaP-IPV and ActHIB® TARGET	DTaP-IPV and ActHIB®	Sanofi Pasteur, a Sanofi Company	phase 3	Vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
TT infant whole Pertussis	TT infant whole Pertussis	London School of Hygiene and Tropical Medicine	marketed	vaccine
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
vaccinated with bOPV	vaccinated with bOPV	Zhejiang Provincial Center for Disease Control and Prevention	marketed	vaccine
VI	VI	GlaxoSmithKline	marketed	Recombinant zoster vaccine	Varicella zoster virus glycoprotein E (gE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Vaccine class)

GlaxoSmithKline · 16 drugs in this class
Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
Pfizer · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Henogen · 3 drugs in this class
Pfizer Inc. · 2 drugs in this class
Sanofi · 2 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
BioNTech · 2 drugs in this class
Merck Sharp & Dohme LLC · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DTaP-IPV and ActHIB® — Competitive Intelligence Brief. https://druglandscape.com/ci/dtap-ipv-and-acthib. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab